Introduction {#sec1}
============

The dopamine D~4~ receptor (D~4~R) is a G protein-coupled receptor and a member of the D~2~-like subfamily of dopamine receptors (including D~2~R, D~3~R, and D~4~R). D~2~-like receptors have high sequence homology and share a G~αi/o~-coupled signaling mechanism, but differ substantially in localization within the brain and at the subcellular level.^[@ref1]^ Compared with D~2~Rs and D~3~Rs, D~4~Rs have the lowest level of expression in the brain and show a unique distribution pattern, with most located in the prefrontal cortex (PFC) and hippocampus. The other D~2~-like receptors are primarily in the striatum, basal ganglia, and pituitary gland regions, regions associated with D~2~R-targeting antipsychotic drugs and the motor and endocrine side effects commonly observed with them.^[@ref2],[@ref3]^ In contrast, D~4~Rs expressed in PFC and hippocampus affect attention, exploratory behavior,^[@ref3]^ and performance in novel object recognition^[@ref4],[@ref5]^ and inhibitory avoidance^[@ref6]^ cognitive tasks. Therefore, pharmacological activation of D~4~Rs may be useful to treat cognitive deficits associated with schizophrenia^[@ref7]−[@ref10]^ and attention-deficit/hyperactivity disorder.^[@ref10],[@ref11]^ Additional research has explored D~4~R agonism as a strategy to reduce the adverse effects of opioid drugs like morphine.^[@ref12],[@ref13]^ D~4~R antagonism may be useful to treat substance use disorders (SUDs), particularly psychostimulant addiction, and [l]{.smallcaps}-DOPA-induced dyskinesias.^[@ref10],[@ref14]−[@ref20]^ The importance of targeting D~4~Rs in treating these complex pathologies, especially with regards to the extent of receptor activation or inhibition, remains unknown, partially because of a lack of suitable compounds for investigating these pathways.

A-412997 (**1**, 2-(4-(pyridin-2-yl)piperidin-1-yl)-*N*-(*m*-tolyl)acetamide, [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) was initially characterized as a "full agonist" (83% intrinsic activity) at D~4~R, with high selectivity over D~2~R and D~3~R and in vivo effects that included induction of penile erection in rats.^[@ref21],[@ref22]^ Subsequent in vivo evaluations showed improved cognitive performance in social recognition tasks, novel object recognition tasks, and 5-trial repeated acquisition inhibitory avoidance tasks following treatment by **1** \[or similar D~4~R agonists PD168077 (**2**) and CP226269 (**3**)\], suggesting an important role for D~4~R signaling in mediating short-term memory and cognition.^[@ref5],[@ref23]^

![Three classic D~4~R-selective partial agonists.](jm-2019-00231b_0001){#fig1}

The goals of this study were to develop new D~4~R agonists with a range of efficacy levels and to identify the molecular components that engender ligand efficacy at D~4~R. To that end, we employed a rational drug design strategy incorporating classic structure--activity relationship (SAR) analysis around lead compound **1**. These studies were enhanced by detailed in silico molecular dynamics (MD) simulations exploiting the recently reported crystal structure of D~4~R.^[@ref24]^ Furthermore, comparative analyses were done using the D~3~R crystal structure^[@ref25]^ and the recently reported D~2~R structure.^[@ref26]^

We synthesized a library of analogues primarily featuring modifications in the phenylpiperidinyl region of **1**, with additional variations in linker chain length and substitutions on the amidylphenyl region. Following extensive in vitro analyses, including binding and functional studies, we determined that selected modifications resulted in novel analogues with improved subtype selectivity. Furthermore, we identified three classes of modifications that resulted in altered efficacy profiles at all D~2~-like receptors. In order to determine key receptor--ligand interactions, and identify the molecular substrates of a putative "efficacy switch," the library was docked in receptor models of D~2~R, D~3~R, and D~4~R using MD simulations.

Chemistry {#sec2}
=========

Ligands were synthesized as outlined in [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"} using routine N-alkylation reactions previously reported.^[@ref21],[@ref27]^ The commercially available *m*-toluidine **4** was converted to intermediate 2-chloro-*N*-(*m*-tolyl)acetamide **5** by reacting with 2-chloroacetyl chloride in the presence of triethylamine and ethyl acetate at room temperature.^[@ref28]^ Using the same procedure, intermediates **14**, **19**, and **24** were synthesized in a similar manner, as indicated in [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}, with either a one- or two-carbon linker. The intermediate compounds **5**, **14**, **19**, and **24** were used to alkylate different commercially available arylpiperazine or arylpiperidine amines in the presence of K~2~CO~3~ in CH~3~CN under reflux conditions to yield the desired target compounds **6--9**, **10--13**, **15--17**, **20--22**, and **25--28**, respectively, with the exception of the synthesis of 1-(naphthalen-1-yl)piperazine which was previously reported^[@ref29]^ via nucleophilic substitution reaction with naphthalen-1-amine.

![Synthesis of 2-(4-(Pyridin-2-yl)piperidin-1-yl)-*N*-(*m*-tolyl)acetamide Analogues\
Reagents and conditions: (a) triethylamine, EtOAc, RT; (b) CH~3~CN, K~2~CO~3~, reflux, appropriate arylpiperazine or arylpiperidine.](jm-2019-00231b_0010){#sch1}

Pharmacological Results and Discussion {#sec3}
======================================

SARs at Dopamine D~2~-like Receptors {#sec3.1}
------------------------------------

A primary objective of this study was to design ligands with high D~4~R binding affinity and subtype selectivity. The compound **1** and several designed analogs are shown in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}. In order to obtain D~4~R ligands with high affinity and selectivity, using compound **1** as our lead compound, we employed three modification strategies, creating 2-(piperidin-4-yl)pyridinyl analogs, altering the linker chain length, and creating *N*-(*m*-tolyl)acetamide analogs.

![Three classes of modifications to the structure of **1** resulting in differing binding and efficacy profiles at D~2~-like receptors. (A) Substitution of the piperidine ring for piperazine induced a gain of efficacy at D~2~R and D~3~R with insubstantial changes to D~4~R efficacy. (B) Substitution of the pyridine ring with a phenyl or napthyl moiety produced modest D~4~R subtype selectivity improvements and lowered partial agonist efficacy at D~4~R with no agonist activity at D~2~R or D~3~R. (C) Para-substituted pyridine rings produced highly D~4~R-selective antagonists.](jm-2019-00231b_0002){#fig2}

Of note, when **1** was evaluated in two different functional assays, its profile was clearly that of a partial agonist rather than a full agonist as it is often described in the literature. In the agonist mode for both the cyclic AMP (cAMP) accumulation and β-arrestin recruitment assays, **1** had an *E*~max~ of 61.9 and 22.5%, respectively, when normalized to dopamine.

The 2-pyridine moiety of **1** was replaced with a phenyl in **6**, *para*-tolyl in **7**, 4-chlorophenyl in **8**, and 5-methylpyridin-2-yl in **9**. The piperidine attached to the linker chain was replaced with a piperazine to form **10**, replaced with a pyrimidine to form **11**, replaced with a 5-chloropyridin-2-yl to form **12**, and replaced with a naphthyl substituent to obtain **13**. To evaluate the contribution of the alkyl chain to the binding affinity and selectivity, we synthesized alkyl chain length analogs of compounds **1**, **10**, and **11**, adding an extra methylene to the linker chain in compounds **15**, **16**, and **17**, respectively. Finally, we probed the contribution of the *N*-(3-methylphenyl)acetamide moiety via replacement of the methyl with ethyl (compounds **20**, **21**, and **22**, compared to compounds **1**, **10**, and **12**, respectively) or replaced of the entire *N*-(3-methylphenyl)acetamide moiety with heteroaromatics (compounds **25--28**).

In order to best evaluate comparative affinities, two different radioligands were used in competition binding studies: \[^3^H\]*N*-methylspiperone, a high-affinity D~2~-like antagonist, and \[^3^H\]-(*R*)-(+)-7-OH-DPAT, a D~2~-like agonist. Importantly, the binding affinities of D~2~-like agonists and high-efficacy partial agonists are considerably higher when competing against an agonist radioligand because high-affinity agonist binding incorporates an efficacy measure in that the greater the efficacy for inducing G protein coupling, the greater the "apparent" affinity will be. On the other hand, antagonist binding, and competition for it, is unlinked from efficacy and therefore unbiased. Therefore, because these radioligands probe different receptor states, they provide complimentary views of ligand binding,^[@ref30]^ which are particularly valuable when examining affinity of partial agonists.

Several modifications of **1** resulted in modest improvements in D~4~R affinity as measured by competition assays with \[^3^H\]*N*-methylspiperone (up to ∼3-fold) and \[^3^H\]-(*R*)-(+)-7-OH-DPAT (up to ∼3-fold). However, marked improvements in D~4~R selectivity over D~2~R and D~3~R resulted from a variety of modifications, typically driven by a loss of affinity at D~2~R and D~3~R.

2-Pyridine substitutions resulted in a potency gain when the piperidinyl moiety was replaced with piperazinyl (e.g., **10** and **21**). Adding an extra methylene to the linker chain, as in compounds **15**, **16**, and **17**, significantly diminished D~4~R affinity and selectivity. These results are consistent with previous studies that determined the importance of carboxamide linker length for D~2~-like receptor selectivity.^[@ref31]^ Replacement of the methyl with an ethyl at the *N*-(3-methylphenyl)acetamide moiety (compounds **20**, **21**, and **22**) did not substantially alter affinity or selectivity for D~4~R compared to methyl analogues **1**, **10**, and **12**, respectively. Replacement of the entire *N*-(3-methylphenyl)acetamide moiety with heteroaromatics (compounds **25--28**) uniformly led to loss of affinity and selectivity.

Overall, we noted three broader classes of modifications with distinct binding and efficacy profiles across the D~2~-like receptors; as outlined in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}, these include (1) substitution of the piperidine ring for piperazine, (2) substitution of the pyridine ring with a phenyl or napthyl moiety, and (3) para-substituted pyridine rings. These classes formed the basis for further SAR profiling and modeling studies using MD simulations.

The parent compound, **1**, showed 115-fold and 31-fold higher affinity for D~4~R over D~2~R and D~3~R, respectively, as measured by \[^3^H\]*N*-methylspiperone competition. When examined using \[^3^H\]-(*R*)-(+)-7-OH-DPAT competition, **1** had higher affinity at all subtypes (consistent with an agonist radioligand being displaced by a compound that favors the activated receptor^[@ref30]^) and showed a similar selectivity profile of 64-fold and 42-fold higher affinity for D~4~R over D~2~R and D~3~R, respectively. Full binding results are presented in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}. Functional characterization revealed **1** to be a partial agonist at D~4~R as measured in β-arrestin assays (*E*~max~ = 22.5%, EC~50~ = 473 nM) ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A,B) and cAMP inhibition assays (*E*~max~ = 61.9%, EC~50~ = 2.7 nM) ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}B,C). The higher efficacy observed in the cAMP assay is likely due to spare receptors and/or amplification of cAMP accumulation versus recruitment of β-arrestin. Consistent with a partial agonist profile, **1** and related analogs were partial antagonists when run in antagonist mode ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}B,D), blocking function to a similar degree as their maximal agonist activity. This would be expected for a compound that is a partial agonist that maintains affinity for the orthosteric part of the receptor, thereby acting as a partial antagonist in antagonist assays. Importantly, **1** showed no measurable agonist response on D~2~R-mediated β-arrestin recruitment but behaved as a low affinity full antagonist ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}E). Furthermore, **1** has very low potency and efficacy at the D~3~R ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}F). Complete functional results are presented in [Tables [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"} and [3](#tbl3){ref-type="other"}. These data indicate that **1** is a potent and highly selective partial agonist at the D~4~R.

![Compounds **10** (red) and **21** (gray) show similar pharmacology to parent compound **1** (black). D~4~R-expressing stable cells lines were plated and compounds were assayed for agonist (A) and antagonist (B) activity on β-arrestin recruitment. Similarly, D~4~R-mediated inhibition of cAMP accumulation was also examined in both agonist (C), and antagonist (D) modes, as indicated. Assays were conducted as described in the [Experimental Methods](#sec5){ref-type="other"}; briefly, agonist assays were conducted by incubating the cells with the indicated concentration of test compound and measuring luminescence. Antagonist assays were conducted by incubating the compound with an EC~80~ concentration of dopamine (1 μM for β-arrestin and 10 nM in cAMP) and the indicated concentration of the test compound. For cAMP assays, cells were first stimulated with 10 μM forskolin. Agonist mode assays are expressed as a percentage of the maximum dopamine response, whereas antagonist mode assays are expressed as a percentage of dopamine's EC~80~ response. *E*~max~ and EC~50~ values are shown in [Tables [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"} and [3](#tbl3){ref-type="other"}. Data were fit using nonlinear regression of individual experiments performed in triplicate and are shown as means ± SEM; *n* = 3. Dopamine and sulpiride were run during each assay as positive controls for a full agonist and full antagonist respectively (data not shown). Compounds were also tested for both agonist and antagonist activity on cells stably expressing the closely related D~2~R (E) or D~3~R (F). Assays were conducted as described in the [Experimental Methods](#sec5){ref-type="other"}. Agonist mode assays (open symbols) are expressed as a percentage of the maximum dopamine response observed for each receptor, whereas antagonist mode assays (solid symbols) are expressed as a percentage of dopamine's EC~80~ response. *E*~max~ and EC~50~ values are shown in [Tables [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"} and [3](#tbl3){ref-type="other"}. Data were fit using nonlinear regression of individual experiments performed in triplicate and are shown as means ± SEM; *n* = 3.](jm-2019-00231b_0003){#fig3}

###### Human Dopamine D~2~-like Receptor Binding Data in HEK293 Membranes for Ligands with Varying Arylpiperazine and Arylamide Moieties[a](#t1fn1){ref-type="table-fn"}

![](jm-2019-00231b_0011){#GRAPHIC-d7e1254-autogenerated}

![](jm-2019-00231b_0012){#gr11}

*K*~i~ values determined by competitive inhibition of \[^3^H\]*N*-methylspiperone or \[^3^H\]-(*R*)-(+)-7-OH-DPAT binding in membranes harvested from HEK293 cells stably expressing hD~2~R, hD~3~R, or hD~4~R. All *K*~i~ values are presented as means ± SEM.

###### Efficacy as Measured via Modulation of cAMP Accumulation[a](#t2fn1){ref-type="table-fn"}

           D~2~R efficacy   D~4~R efficacy   EC~50~        IC~50~                                                                            
  -------- ---------------- ---------------- ------------- ---------------- ------------ -------------- ------------- --------------- ------ --------
  **1**    inactive         inactive         ND            \>50000          61.9 ± 4.7   2.7 + 0.9      53.8 ± 6.0    68.4 ± 32.8     ND     \>735
  **6**    inactive         inactive         100 + 0.00    16447 + 3540     32.9 ± 3.9   15.4 ± 13.2    46.7 ± 6.0    2.0 ± 0.05      ND     8224
  **7**    inactive         inactive         100 ± 0       44834 ± 28125    inactive     inactive       95.8 ± 2.2    3064 ± 1220     ND     15
  **8**    inactive         inactive         97.5 ± 2.5    71437 ± 28563    inactive     inactive       100 ± 0       70157 ± 20766   ND     1.0
  **9**    inactive         inactive         100 ± 0       71065 ± 20 585   inactive     inactive       100 ± 0       453 ± 15        ND     157
  **10**   18.96 ± 5.2      763 ± 386        ND            \>100000         64.2 ± 5.7   3.6 ± 1.3      43.2 ± 1.8    82.7 ± 37.9     214    \>1210
  **11**   54.4 ± 7.5       2092 ± 46        ND            \>100000         64.6 ± 4.2   3.4 + 2.0      45.0 ± 7.7    463 ± 157       612    \>216
  **15**   83.1 ± 4.2       50.1 ± 25        ND            \>100000         28.1 ± 1.6   349 ± 75       77.6 ± 5.2    6343 ± 2524     0.14   \>16
  **16**   79.7 ± 8.4       154 ± 31         ND            \>100000         30.0 ± 2.1   612 ± 563      84.2 ± 6.0    1629 ± 255      0.25   \>61
  **17**   inactive         inactive         ND            \>100000         13.7 ± 1.2   568 ± 456      87.0 ± 3.4    2120 ± 534      ND     \>47
  **12**   inactive         inactive         98.3 ± 1.7    66077 ± 18646    inactive     inactive       93.4 ± 2.6    4701 ± 1466     ND     14
  **13**   inactive         inactive         100 ± 0       68329 ± 31671    27.8 ± 8.4   108.5 ± 94.3   73.8 ± 13.6   2521 ± 1067     ND     27
  **20**   inactive         inactive         96.6 ± 3.5    16278 ± 11601    25.6 ± 7.2   539 ± 151      70.8 ± 15     1908 ± 242      ND     9
  **21**   18.80 ± 8.19     1600 ± 396       88 ± 6.1      40466 ± 29968    58.0 ± 1.8   28.7 ± 9.9     58.4 ± 9.7    1311 ± 814      56     31
  **22**   inactive         inactive         100 ± 0       46795 ± 27644    inactive     inactive       100 ± 0       7059 ± 1136     ND     7
  **25**   38.6 ± 3         1965 ± 44        100 ± 0       \>100000         47.3 ± 7.9   1075 ± 390     100 ± 0       86493 ± 3130    2.0    \>1.1
  **26**   inactive         inactive         100 ± 0       86617 ± 13383    inactive     inactive       100 ± 0       40000 ± 9421    ND     2
  **27**   inactive         inactive         98.1 ± 1.5    94255 ± 5745     inactive     inactive       100 ± 0       \>100000        ND     \<1
  **28**   inactive         inactive         76.2 ± 17.6   72516 ± 18052    inactive     inactive       100 ± 0       \>100000        ND     \<1

Values determined by nonlinear regression of individual experiments run in triplicate as detailed in materials and methods under cAMP accumulation assays. All EC~50~, IC~50~, and *E*~max~ values are presented as means ± SEM; *n* = 3--4. ND indicates not determined due to an incomplete curve. Inactive indicates no measurable activity in indicated assay.

A measure of agonism as defined by the maximum inhibition of cAMP observed for each compound.

A measure of antagonism as defined by the maximum blockade of dopamine mediated cAMP inhibition by each compound.

###### Efficacy as Measured via Modulation of β-Arrestin Recruitment[a](#t3fn1){ref-type="table-fn"}

           D~2~R efficacy   D~3~R efficacy   D~4~R efficacy   EC~50~          IC~50~                                                                                                                              
  -------- ---------------- ---------------- ---------------- --------------- ------------- ------------- ---------- --------------- ------------- ------------- ------------ --------------- ---- ------ ------- -------
  1        inactive         inactive         94.8 ± 2.8       5846 ± 1802     ND            \>100000      ND         \>100000        22.5 ± 3.98   473 ± 457     81.7 ± 2.7   191 ± 98        ND   \>4    31      \>524
  6        inactive         inactive         99.7 ± 0.3       7692 ± 2301     inactive      inactive      ND         \>50000         14 ± 0.3      242 ± 89      93.3 ± 1.8   135 ± 65        ND   ND     57      \>371
  7        inactive         inactive         100 ± 0          89153 ± 10847   inactive      inactive      inactive   inactive        inactive      inactive      100 ± 0      7352 ± 1749     ND   ND     12      ND
  8        inactive         inactive         100 ± 0          \>100000        inactive      inactive      inactive   inactive        inactive      inactive      100 ± 0      42357 ± 30018   ND   ND     \>2     ND
  9        inactive         inactive         100 ± 0          \>100000        inactive      inactive      inactive   inactive        inactive      inactive      98.1 ± 2     394 ± 78        ND   ND     \>254   ND
  **10**   23.9 ± 5.1       26175 ± 12448    76.5 ± 6.9       16010 ± 5174    49.4 ± 2.0    6354 ± 2617   inactive   \>100000        30.7 ± 6.4    394 ± 294     78.9 ± 3.1   313 ± 215       66   \>16   51      \>320
  **11**   39.6 ± 5.3       8321 ± 3455      78.9 ± 8.6       25008 ± 5017    58.4 ± 6.6    5581 ± 1614   inactive   \>100000        24.7 ± 5      278 ± 167     80.6 ± 3.0   197 ± 115       30   \>20   127     \>509
  **15**   48.9 ± 6.8       2480 ± 1834      72.1 ± 7.9       7627 ± 1573     55.4 ± 1.57   970 ± 115     ND         \>50000         inactive      inactive      98.7 ± 1.0   3805 ± 2944     12   \>5    2.0     \>26
  **16**   44.1 ± 6.3       1455 ± 572       77.7 ± 3.7       7067 ± 2290     41.4 ± 5.83   1601 ± 867    ND         \>50000         inactive      inactive      97.9 ± 1.2   1086 ± 597      ND   \>1    7.0     \>46
  **17**   inactive         inactive         94.6 ± 5.4       11847 ± 2000    inactive      inactive      ND         \>50000         inactive      inactive      97.1 ± 0.8   430 ± 195       ND   ND     28      \>116
  **12**   inactive         inactive         100 ± 0          \>100 000       inactive      inactive      inactive   inactive        inactive      inactive      100 ± 0      7777 ± 2166     ND   ND     \>13    ND
  **13**   inactive         inactive         100 ± 0          \>100 000       inactive      inactive      inactive   inactive        16.4 ± 3.9    9212 ± 6238   96.7 ± 2.7   4252 ± 1077     ND   ND     \>24    ND
  **20**   inactive         inactive         100 ± 0          67613 ± 17748   inactive      inactive      inactive   inactive        inactive      inactive      91.7 ± 6.8   2622 ± 678      ND   ND     26      ND
  **21**   18.7 ± 0.4       3887 ± 1878      100 ± 0          88447 ± 11553   44.7 ± 5.9    2755 ± 472    100 ± 0    88 205 ± 9631   26.2 ± 5.1    133 ± 60.3    59.7 ± 4.6   370 ± 105       29   21     239     238
  **22**   inactive         inactive         100 ± 0          70703 ± 29297   inactive      inactive      inactive   inactive        inactive      inactive      80.4 ± 6.0   10449 ± 2482    ND   ND     6.8     ND
  **25**   21.3 ± 6.8       48503 ± 27571    inactive         inactive        18.6 ± 2.7    2802 ± 2507   inactive   inactive        19.0 ± 2.7    2657 ± 121    100 ± 0      25780 ± 9773    18   1.0    ND      ND
  **26**   inactive         inactive         inactive         inactive        inactive      inactive      inactive   inactive        inactive      inactive      93.1 ± 7     23450 ± 11959   ND   ND     ND      ND
  **27**   inactive         inactive         inactive         inactive        inactive      inactive      inactive   inactive        inactive      inactive      inactive     inactive        ND   ND     ND      ND
  **28**   inactive         inactive         inactive         inactive        inactive      inactive      inactive   inactive        inactive      inactive      100 ± 0      \>100000        ND   ND     ND      ND

Values determined by nonlinear regression of individual experiments run in triplicate as detailed in materials and methods under β-arrestin assays. All EC~50~, IC~50~, and *E*~max~ values are presented as means ± SEM; *n* = 3--4. ND indicates not determined due to an incomplete curve. Inactive indicates no measurable activity in indicated assay.

Replacing the piperidinyl ring of **1** with a piperazine ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}, class 1)---typified by **10** and **21**---resulted in similar binding and agonist efficacy profiles at D~4~R, improved subtype selectivity ([Tables [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} and [2](#tbl2){ref-type="other"}), and a gain in efficacy at both D~2~R and D~3~R ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"} and [Tables [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"} and [3](#tbl3){ref-type="other"}). Replacing the pyridinyl ring of **1** with a phenyl or napthyl moiety ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}, class 2)---typified by **6** and **13**---resulted in improved subtype selectivity, and importantly a diminished-efficacy partial agonist profile at D~4~R. These compounds showed no measurable agonist efficacy at either D~2~R or D~3~Rs ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}). A para-substitution on the pyridinyl ring of **1** ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}, class 3)---typified by **12** and **9**---resulted in compounds that lost all agonist efficacy but retained high-affinity binding at D~4~R, with very minimal binding at D~2~R or D~3~R. The compounds showed potent antagonism of the D~4~R response with minimal low potency D~2~R blockade and no measurable affinity or efficacy at D~3~R. Therefore, this class of compounds represents highly selective D~4~R antagonists with no measurable agonist efficacy on any D~2~-like receptor ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}, [Tables [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}--[3](#tbl3){ref-type="other"}).

![Compounds **13** (yellow) and **6** (blue) show diminished agonist activity at the D~4~R compared to parent compound **1** (black). D~4~R-expressing stable cells lines were plated and compounds were assayed for agonist (A) and antagonist (B) activity on β-arrestin recruitment. Similarly, D~4~R-mediated inhibition of cAMP accumulation was also examined in both agonist (C), and antagonist (D) modes, as indicated. Assays were conducted as described in the [Experimental Method](#sec5){ref-type="other"}s; briefly, agonist assays were conducted by incubating the cells with the indicated concentration of test compound and measuring luminescence. Antagonist assays were conducted by incubating the compound with an EC~80~ concentration of dopamine (1 μM for β-arrestin and 10 nM in cAMP) and the indicated concentration of test compound. For cAMP assays, cells were first stimulated with 10 μM forskolin. Agonist mode assays are expressed as a percentage of the maximum dopamine response, whereas antagonist mode assays are expressed as a percentage of dopamine's EC~80~ response. *E*~max~ and EC~50~ values are shown in [Tables [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"} and [3](#tbl3){ref-type="other"}. Dopamine and sulpiride were run during each assay as positive controls for a full agonist and full antagonist, respectively (data not shown). Data were fit using nonlinear regression of individual experiments performed in triplicate and are shown as means ± SEM; *n* = 3.](jm-2019-00231b_0004){#fig4}

![Compounds **12** (green) and **9** (purple) are full antagonists at the D~4~R. D~4~R-expressing stable cells lines were plated and compounds were assayed for agonist (A) and antagonist (B) activity on β-arrestin recruitment. Similarly, D~4~R-mediated inhibition of cAMP accumulation was also examined in both agonist (C), and antagonist (D) modes, as indicated. Assays were conducted as described in the [Experimental Methods](#sec5){ref-type="other"}; briefly, agonist assays were conducted by incubating the cells with the indicated concentration of test compound and measuring luminescence. Antagonist assays were conducted by incubating the compound with an EC~80~ concentration of dopamine (1 μM for β-arrestin and 10 nM in cAMP) and the indicated concentration of test compound. For cAMP assays, cells were first stimulated with 10 μM forskolin. Assays were conducted as described in the [Experimental Methods](#sec5){ref-type="other"}. Agonist mode assays are expressed as a percentage of the maximum dopamine response, whereas antagonist mode assays are expressed as a percentage of dopamine's EC~80~ (1 μM in β-arrestin and 10 nM in cAMP) response. *E*~max~ and EC~50~ values are shown in [Tables [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"} and [3](#tbl3){ref-type="other"}. Dopamine and sulpiride were run during each assay as positive controls for a full agonist and full antagonist respectively (data not shown). Data were fit using nonlinear regression of individual experiments performed in triplicate and are shown as means ± SEM; *n* = 3.](jm-2019-00231b_0005){#fig5}

Individual compounds within classes 1--3 resulted in modest changes to overall efficacy and potency as overviewed in [Tables [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}--[3](#tbl3){ref-type="other"}. For this reason, we chose to focus on typified examples of a range of agonist efficacy (higher, medium, and none) at the D~4~R. Using these classes, we performed MD simulations to identify interaction sites on the receptor that may play a pivotal role in engendering agonist selectivity and efficacy.

MD Studies {#sec3.2}
----------

To gain insights on probable ligand interactions at D~4~R, a set of seven ligands from the parent compound and the three class of modifications (i.e., **1**, **6**, **9**, **10**, **12**, **13**, and **21**) were docked to the crystal structures of D~2~R,^[@ref26]^ D~3~R,^[@ref25]^ and D~4~R.^[@ref24]^ Each receptor--ligand combination was subjected to 100 ns MD simulations, followed by the simulation interaction diagram (SID) and clustering analysis as described in the [Experimental Methods](#sec5){ref-type="other"} section. The results are included in the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.9b00231/suppl_file/jm9b00231_si_001.pdf) (Tables S2--S4 and Figures S2--S39). Comparisons of structural and dynamic properties of each ligand--receptor system, with reference to the parent compound **1** for each receptor system, are listed in [Table S1](http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.9b00231/suppl_file/jm9b00231_si_001.pdf). Although the same class modifications caused similar changes in the majority of the analyzed properties, some subtle differences are also identified. A representative ligand--receptor system from each class modification is presented here.

In order to explore class 1 modifications that showed a gain of efficacy at D~2~R and D~3~R with minimal changes in D~4~R binding or efficacy, **10** was selected to be presented here along with parent compound **1**. The comparative ligand binding at of **10** D~2~R ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}) and D~3~R ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}) revealed that the modest ligand change---the substitution of a piperazine for a piperidine---induced a dramatic shift in the binding orientation at D~2~R and D~3~R: compared to the parent compound **1**, **10** took on a rotated orientation in both receptors, in which the arylamide portion of the **10** occupies a region of the binding pocket that accommodates the 2-(piperidin-4-yl)pyridinyl portion of **1**. This pose allows **10** to better engage with the conserved transmembrane (TM) 3 aspartate residue (D^3.32^) located within the orthosteric binding pocket of biogenic amine receptors like dopaminergic receptors.^[@ref32]^ Additionally, there was new engagement with conserved V^2.61^, and additional TM5 and TM6 helix shifts in both receptors. In contrast, the binding orientation of **10** at D~4~R is similar to that of **1** ([Figure S7](http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.9b00231/suppl_file/jm9b00231_si_001.pdf)), although a shift in the orientation of the pyridinylpiperidine ring system deeper into the receptor was observed. **21** docked similarly to **10** at D~2~R and at D~4~R (i.e., rotated 180° in comparison to **1**), but differed at D~3~R in which the pose was similar to that of **1**, possibly indicating a different activation mechanism for D~3~R by this compound.

![**1** and **10** docked at D~2~R. (A--D) Comparative alignment of **1** (red ligand, yellow TM domains) and **10** (blue ligand, purple TM domains) following MD simulations of the D~2~R (PDB: 6CM4([@ref26])). (E--H) Analysis of ligand interactions with specific side chains of **1** (E,G) and **10** (F,H). Although the structural difference between **1** and **10** is only a piperidine vs a piperazine ring, this drives a dramatic shift in ligand orientation in which **10** is "flipped" and rotated by 180° about its longitudinal axis, with its pyridine ring deepest in the binding pocket. This allows the basic nitrogen of the neighboring piperazine ring to engage the conserved aspartate in TM3, a common feature of dopaminergic agonists.](jm-2019-00231b_0006){#fig6}

![**1** and **10** docked at D~3~R. (A--D) Comparative alignment of **1** (red ligand, yellow TM domains) and **10** (blue ligand, purple TM domains) following MD simulations of the D~3~R (PDB: 3PBL([@ref25])). (E--H) Analysis of ligand interactions with specific side chains of **1** (E,G) and **10** (F,H). As seen in the D~2~R model, **10** is also "flipped" and rotated by 180° about its longitudinal axis in the binding pocket at D~3~R compared to **1**. This allows for a different set of hydrophobic interactions and the engagement of the basic nitrogen of the piperazine ring to with the conserved aspartate in TM3.](jm-2019-00231b_0007){#fig7}

**13** ([Figure [8](#fig8){ref-type="fig"}](#fig8){ref-type="fig"}), representing class 2 modifications that showed a partial loss of efficacy at D~4~R, and **9** ([Figure [9](#fig9){ref-type="fig"}](#fig9){ref-type="fig"}), representing class 3 modifications that showed a complete loss of efficacy at D~4~R, are shown in models of D~4~R alongside the parent compound **1**. **13** uniquely engaged with S^2.64^, E^2.65^, and T^7.39^, and induced conformational shifts in several TM domains and intra/extracellular loops. **9** showed grater engagement with ECL2 and uniquely interacted with C^3.25^ and W^6.48^. Whereas **13** adopted a pose similar to **1**, **9** adopted a rotated orientation in which the arylamide portion of the **9** occupies a region of the binding pocket that accommodates the 2-(piperidin-4-yl)pyridinyl portion of **1** ([Table S1](http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.9b00231/suppl_file/jm9b00231_si_001.pdf)). The results seen in these two comparisons are consistent with previous observations in which regiosubstitutions on an aryl ring of a terminal arylpiperazine can modulate efficacy at D~4~R.^[@ref33],[@ref34]^ In particular, the inclusion of a para substitution on the terminal arylpiperazine has reliably produced D~4~R antagonists for a wide variety of molecules with diverse substituents on the secondary pharmacophore.

![**1** and **13** docked at D~4~R. (A--D) Comparative alignment of **1** (red ligand, yellow TM domains) and **13** (blue ligand, purple TM domains) following MD simulations of the D~4~R (PDB: 5WIU([@ref24])). (E--H) Analysis of ligand interactions with specific side chains of **1** (E,G) and **13** (F,H). The bulky napthyl ring of **13** shifts the overall fit within the extended binding pocket, partially disrupting the engagement of the basic nitrogen of the piperazine ring to with the conserved aspartate in TM3.](jm-2019-00231b_0008){#fig8}

![**1** and **9** docked at D~4~R. (A--D) Comparative alignment of **1** (red ligand, yellow TM domains) and **9** (blue ligand, purple TM domains) following MD simulations of the D~4~R (PDB: 5WIU([@ref24])). (E--H) Analysis of ligand interactions with specific side chains of **1** (E,G) and **9** (F,H). The inclusion of a single para substitution on the pyridine ring of **9** induces a "flipped" orientation of the ligand, in which the binding pose is rotated by 180° about its longitudinal axis, with its pyridine ring deepest in the binding pocket driving the arylamide into a deeper binding position.](jm-2019-00231b_0009){#fig9}

Conclusions {#sec4}
===========

Evidence from human genetic studies and animal models suggest that D~4~R signaling may mediate behavioral traits including impulsivity,^[@ref35]^ novelty seeking,^[@ref35]−[@ref38]^ fear and anxiety,^[@ref39],[@ref40]^ and sensitivity to drugs of abuse.^[@ref40]−[@ref43]^ While modulation of postsynaptic D~4~R expression in the PFC is typically hypothesized to mediate the reported in vivo effects of D~4~R agonists and antagonists, evidence suggests important roles of D~4~R expression in the nucleus accumbens shell^[@ref44]^ and within the lateral habenula,^[@ref45]^ in which the receptor may be preferentially activated by norepinephrine rather than dopamine.^[@ref46],[@ref47]^ Furthermore, little is known about the physiological relevance of independent D~4~R-mediated signaling pathways (e.g., cAMP and β-arrestin) in the manifestation of behavioral outputs. A recent report identified a D~4~R-selective compound containing an unsubstituted phenylpiperazine that potently and partially activated G~αi~ but inhibited β-arrestin2 recruitment and identified likely ligand--residue interactions that affect receptor activation states.^[@ref48]^ There is much left to be determined about the physiological role of D~4~R signaling in modulating attention and cognitive processes, and new selective agonists and antagonists of these receptors will be valuable tools for deduction of signaling importance by these receptors.

New highly selective D~4~R partial agonists and antagonists will be useful to better characterize the role of D~4~R signaling in vivo. While we have primarily focused on selectivity against the very closely related D~2~R and D~3~R, it will be important to establish global selectivity of these compounds for in vivo experimentation through a broader screening of biogenic amine receptors. To this end, we investigated a subset of these compounds on the related D~1~-like DARs. None of the tested compounds showed any measurable agonist or antagonist effect at either the D~1~R or D~5~R ([Figure S1](http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.9b00231/suppl_file/jm9b00231_si_001.pdf)). Comprehensive binding and functional studies, in concert with detailed molecular modeling analyses using newly published crystal structures, provides a platform for developing high-affinity and highly subtype selective ligands of varying efficacies. This study aimed to identify key molecular interactions that dictate D~4~R potency, efficacy, and subtype selectivity.

The parent compound, **1**, was confirmed to be a high-affinity (low nM *K*~i~ value) partial agonist (*E*~max~ = 23--62%) at D~4~R. Illustrative of broader trends from our library, the compound *K*~i~ values for all D~2~-like receptors determined using \[^3^H\]-(*R*)-(+)-7-OH-DPAT competition assays tended to be lower (more potent) than those obtained using \[^3^H\]*N*-methylspiperone. As expected, the divergence between these values increased with agonist efficacy, consistent with previous experience regarding agonist versus antagonist radioligands.^[@ref30]^

Key modifications to the **1** pharmacophore provided modest gains to D~4~R affinity, but dramatic gains in selectivity over D~2~R and D~3~R, likely because of a substantial decrease in D~2~R and D~3~R engagement by the analogs. Interestingly, the manner of these substitutions produced three classes of lead compound: (1) those with binding and efficacy profiles similar to **1** at D~4~R but gains in efficacy at D~2~R and D~3~R; (2) those with improved D~4~R binding and subtype selectivity with lower partial agonist efficacy; and (3) those with improved D~4~R binding and subtype selectivity with full antagonist characteristics. MD simulations suggest that the gain in D~2~R and D~3~R efficacy seen in compounds like **10** could be partially due to achieving a rotated ligand pose that more fully engages the conserved TM3 aspartate. Similarly, the complete shift to antagonism at D~4~R seen in compounds like **9** could be partially due to inducing an alternate binding pose that either no longer allows full engagement of the orthosteric binding site and occupation of an alternative secondary binding pocket or a ligand-dependent alteration of the receptor energy landscape leading to the stabilization of a different receptor conformation.

These molecular models provide testable predictions relative to the unique interaction sites of these diverse compounds within the D~4~R. These interactions likely underlie agonist efficacy of a given compound. Interestingly, compounds can be "rank ordered" by levels of agonist efficacy starting with **1** having the highest D~4~R activation, followed by class 1 compounds (which show similar agonist efficacy) and then class 2 compounds (which show less agonist efficacy) and class 3 compounds that lack any agonist efficacy. As expected, these compounds align the opposite way for antagonist efficacy, wherein a lower agonist efficacy correlates with a higher antagonist efficacy. Examined this way, one can see that it may be possible to "dial-in" or "dial-out" levels of D~4~R stimulation via adjusting compound structure, and therefore interaction sites on the receptor, leading to divergent levels of partial agonism. Future studies will involve further SAR and receptor mutagenesis studies to verify these models. We are optimistic that some of the analogues may be developed into useful in vivo research tools and plan to examine absorption, distribution, metabolism, and excretion characteristics of selected analogues. It is interesting to speculate that a collection of partial agonists with varying efficacies may allow for the fine-tuning of D~4~R activation, potentially leading to a fuller understanding of functional consequences of varying signaling levels for D~4~R-targeted therapeutics for neuropsychiatric disorders.

Experimental Methods {#sec5}
====================

Synthesis {#sec5.1}
---------

Reaction conditions and yields were not optimized. Anhydrous solvents were purchased from Aldrich and were used without further purification. All other chemicals and reagents were purchased from Sigma-Aldrich Co. LLC, Combi-Blocks, TCI America, OChem Incorporation, Acros Organics, and Alfa Aesar. All amine final products were converted into either the oxalate or hydrochloride salt. Spectroscopic data and yields refer to the free base form of compounds. Flash chromatography was performed using silica gel (EMD Chemicals, Inc.; 230--400 mesh, 60 Å) by using a Teledyne ISCO CombiFlash RF system. ^1^H NMR spectra were acquired using a Varian Mercury Plus 400 spectrometer at 400 MHz. Chemical shifts are reported in parts-per-million and referenced according to deuterated solvent for ^1^H spectra (CDCl~3~, 7.26, CD~3~OD, 3.31 or D~2~O, 4.79). Combustion analysis was performed by Atlantic Microlab, Inc., (Norcross, GA), and the results agree within ±0.4% of calculated values ([Table S5](http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.9b00231/suppl_file/jm9b00231_si_001.pdf)). Melting point determination was conducted using a Stanford Research Systems OptiMelt automated melting point apparatus and are uncorrected. On the basis of NMR and combustion data, all final compounds are \>95% pure. All compounds within this series are covered under an existing patent,^[@ref49]^ but only **1**,^[@ref21],[@ref22]^**6**,^[@ref22]^ and **10**([@ref16],[@ref21]) have been previously described in the peer-reviewed literature.

General Method A {#sec5.2}
----------------

### 2-Chloro-*N*-(*m*-tolyl)acetamide (**5**)^[@ref21],[@ref27],[@ref28]^ {#sec5.2.1}

2-Chloroacetyl chloride (1.16 g, 10.3 mmol) was added to a solution of *m*-toluidine (1.00 mL, 9.33 mmol) in ethyl acetate (30 mL) and triethylamine (1.43 mL, 10.3 mmol) at 0 °C. The reaction mixture was allowed to warm to room temperature and stirred overnight under a N~2~ atmosphere. After the reaction was complete, the solvent was removed in vacuo. The crude mixture was diluted with water (100 mL) and EtOAc (100 mL) and then extracted with EtOAc (3 × 100 mL) and washed with brine (100 mL). The combined organic layer was dried over MgSO~4~, filtered, and concentrated. The product was purified by column chromatography (10--90% EtOAc/hexanes gradient) to give **5** (1.30 g, 76% yield) as an off-white solid. ^1^H NMR (CDCl~3~): δ 8.19 (s, 1H), 7.38--7.33 (m, 1H), 7.26--7.22 (m, 1H), 6.99 (d, *J* = 7.6 Hz, 1H), 4.18 (s, 2H), 2.36 (s, 3H).

General Method B {#sec5.3}
----------------

### 2-(4-Phenylpiperidin-1-yl)-*N*-(*m*-tolyl)acetamide (**6**; CAB03-015)^[@ref21],[@ref22],[@ref27],[@ref28]^ {#sec5.3.1}

K~2~CO~3~ (2.57 g, 18.6 mmol) and NaI (50 mg) were added to a solution of 2-chloro-*N*-(*m*-tolyl)acetamide (570 mg, 3.10 mmol) and commercially available 4-phenylpiperidine (500 mg, 3.10 mmol) in an anhydrous acetonitrile (12 mL) solution. The reaction mixture was stirred at reflux (80 °C) for 20 h under a N~2~ atmosphere. The reaction mixture was cooled to room temperature, and the solvent was removed in vacuo. The residue was diluted with water (100 mL) and EtOAc (100 mL) and then extracted with EtOAc (3 × 100 mL) and washed with brine (100 mL). The combined organic layer was dried over MgSO~4~, filtered, and concentrated. The crude product was purified by column chromatography (10--90% EtOAc/hexanes gradient) to give pure product **6** (710 mg, 74% yield) as an off-white solid. mp 70--71 °C; ^1^H NMR (CDCl~3~): δ 9.15 (s, 1H), 7.42--7.40 (m, 2H), 7.38--7.31 (m, 2H), 7.24--7.20 (m, 4H), 6.93 (d, *J* = 7.2 Hz, 1H), 3.15 (s, 2H), 3.10--3.02 (m, 2H), 2.59--2.52 (m, 1H), 2.43--2.38 (m, 2H), 2.36 (s, 3H), 1.94--1.90 (m, 4H). Anal. (C~20~H~24~N~2~O·HCl·1/4H~2~O) C, H, N.

### *N*-(*m*-Tolyl)-2-(4-(*p*-tolyl)piperidin-1-yl)acetamide (**7**; CAB02-007HP) {#sec5.3.2}

Compound **7** was synthesized as described for **6** using K~2~CO~3~ (1.18 g, 8.56 mmol), NaI (40.0 mg) 4-(*p*-tolyl)piperidine (250 mg, 1.43 mmol), and 2-chloro-*N*-(*m*-tolyl)acetamide (262 mg, 1.43 mmol) in an anhydrous acetonitrile (6 mL) solution. The crude product was purified by column chromatography (15--85% EtOAc/hexanes gradient) to give pure product **7** (182 mg, 40% yield) as a white solid. mp 63--65 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 9.23 (s, 1H), 7.47 (d, *J* = 15.7 Hz, 2H), 7.31 (dd, *J* = 14.4, 5.5 Hz, 2H), 7.23 (d, *J* = 2.9 Hz, 3H), 7.00 (d, *J* = 7.5 Hz, 1H), 3.22 (s, 2H), 3.10 (d, *J* = 11.4 Hz, 2H), 2.58 (d, *J* = 12.5 Hz, 1H), 2.49--2.46 (m, 2H), 2.43 (s, 3H), 2.41 (s, 3H), 1.91 (dt, *J* = 37.8, 13.1 Hz, 4H). Anal. (C~21~H~26~N~2~O·1/4H~2~O·2/5C~3~H~8~O) C, H, N.

### 2-(4-(4-Chlorophenyl)piperidin-1-yl)-*N*-(*m*-tolyl)acetamide (**8**; CAB02-009HP) {#sec5.3.3}

Compound **8** was synthesized as described for **6** using K~2~CO~3~ (715 mg, 5.17 mmol), NaI (40.0 mg) 4-(4-chlorophenyl)piperidine (200 mg, 0.86 mmol), and 2-chloro-*N*-(*m*-tolyl)acetamide (158 mg, 0.86 mmol) in an anhydrous acetonitrile (6 mL) solution. The crude product was purified by column chromatography (40--60% EtOAc/hexanes gradient) to give pure product **8** (120 mg, 41% yield) as a light brownish solid. mp 114--116 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 9.08 (s, 1H), 7.42--7.33 (m, 2H), 7.28 (d, *J* = 8.5 Hz, 1H), 7.24 (d, *J* = 2.4 Hz, 2H), 7.16 (d, *J* = 8.1 Hz, 2H), 6.95--6.88 (m, 1H), 3.13 (s, 2H), 3.01 (t, *J* = 7.1 Hz, 2H), 2.50 (d, *J* = 12.4 Hz, 1H), 2.35 (s, 2H), 2.34 (s, 3H), 1.88 (d, *J* = 13.1 Hz, 2H), 1.76 (q, *J* = 12.7 Hz, 2H). Anal. (C~20~H~23~ClN~2~O) C, H, N.

### 2-(4-(5-Methylpyridin-2-yl)piperidin-1-yl)-*N*-(*m*-tolyl)acetamide (**9**; CAB02-005HP) {#sec5.3.4}

Compound **9** was synthesized as described for **6** using K~2~CO~3~ (1.64 g, 11.9 mmol), NaI (40.0 mg) 5-methyl-2-(piperidin-4-yl)pyridine (350 mg, 1.98 mmol), and 2-chloro-*N*-(*m*-tolyl)acetamide (363 mg, 1.98 mmol) in an anhydrous acetonitrile (6 mL) solution. The crude product was purified by column chromatography (50--50% EtOAc/hexanes gradient) to give pure product **9** (420 mg, 66% yield) as a white solid. mp 126--128 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 9.09 (s, 1H), 8.03 (s, 1H), 7.43--7.30 (m, 3H), 7.20 (d, *J* = 8.2 Hz, 1H), 6.93 (s, 1H), 6.61 (d, *J* = 8.5 Hz, 1H), 3.62--3.49 (m, 3H), 3.18 (br s, 2H), 2.74 (d, *J* = 5.8 Hz, 4H), 2.34 (s, 3H), 2.20 (s, 3H), 1.58--1.52 (m, 2H).

### 2-(4-(Pyridin-2-yl)piperazin-1-yl)-*N*-(*m*-tolyl)acetamide (**10**; CAB02-140)^[@ref22],[@ref27]^ {#sec5.3.5}

Compound **10** was synthesized as described for **6** using K~2~CO~3~ (1.13 g, 6.78 mmol), NaI (40.0 mg) 1-(pyridin-2-yl)piperazine (222 mg, 1.36 mmol), and 2-chloro-*N*-(*m*-tolyl)acetamide (250 mg, 1.36 mmol) in an anhydrous acetonitrile (6 mL) solution. The crude product was purified by column chromatography (20--80% EtOAc/hexanes gradient) to give pure product **10** (330 mg, 78% yield) as a white solid. mp 127--129 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 9.09 (s, 1H), 8.21 (d, *J* = 4.6 Hz, 1H), 7.56--7.46 (m, 1H), 7.39 (d, *J* = 10.1 Hz, 2H), 7.24--7.19 (m, 1H), 6.94 (d, *J* = 7.4 Hz, 1H), 6.68 (q, *J* = 5.5, 4.4 Hz, 2H), 3.62 (t, *J* = 5.0 Hz, 4H), 3.19 (d, *J* = 3.2 Hz, 2H), 2.74 (d, *J* = 5.4 Hz, 4H), 2.35 (d, *J* = 3.2 Hz, 3H), 2.17 (br s, 4H). Anal. (C~18~H~22~N~4~O·2HCl·H~2~O) C, H, N.

### 2-(4-(Pyrimidin-2-yl)piperazin-1-yl)-*N*-(*m*-tolyl)acetamide (**11**; CAB02-110) {#sec5.3.6}

Compound **11** was synthesized as described for **6** using K~2~CO~3~ (1.13 g, 1.16 mmol), 2-(piperazin-1-yl)pyrimidine (223 mg, 1.36 mmol), and 2-chloro-*N*-(*m*-tolyl)acetamide (250 mg, 1.36 mmol) in an anhydrous acetonitrile (6 mL) solution. The crude product was purified by column chromatography (10--90% EtOAc/hexanes gradient) to give pure product **11** (310 mg, 73% yield) as a cream solid. mp 92--94 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 9.16--9.01 (m, 1H), 8.37--8.27 (m, 2H), 7.39 (d, *J* = 14.2 Hz, 2H), 7.22 (d, *J* = 8.1 Hz, 1H), 6.94 (d, *J* = 8.4 Hz, 1H), 6.53 (d, *J* = 4.6 Hz, 1H), 3.91 (s, 4H), 3.18 (q, *J* = 2.1, 1.6 Hz, 2H), 2.69 (d, *J* = 5.6 Hz, 4H), 2.36 (s, 3H). Anal. (C~17~H~21~N~5~O·2HCl·1.75H~2~O) C, H, N.

### 2-(4-(5-Chloropyridin-2-yl)piperazin-1-yl)-*N*-(*m*-tolyl)acetamide (**12**; CAB02-003HP) {#sec5.3.7}

Compound **12** was synthesized as described for **6** using K~2~CO~3~ (1.78 g, 12.86 mmol), NaI (40.0 mg), 1-(5-chloropyridin-2-yl)piperazine (422 mg, 2.14 mmol), and 2-chloro-*N*-(*m*-tolyl)acetamide (400 mg, 2.14 mmol) in an anhydrous acetonitrile (6 mL) solution. The crude product was purified by column chromatography (20--80% EtOAc/hexanes gradient) to give pure product **12** (490 mg, 65% yield) as a white solid. mp 107--109 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 9.02 (s, 1H), 8.11 (d, *J* = 3.3 Hz, 1H), 7.47--7.40 (m, 1H), 7.36 (d, *J* = 11.8 Hz, 2H), 7.19 (d, *J* = 8.5 Hz, 1H), 6.95--6.88 (m, 1H), 6.59 (d, *J* = 8.9 Hz, 1H), 3.58 (t, *J* = 5.2 Hz, 4H), 3.17 (d, *J* = 2.8 Hz, 2H), 2.71 (t, *J* = 5.0 Hz, 4H), 2.33 (s, 3H). Anal. (C~18~H~21~ClN~4~O·2HCl·1/2H~2~O) C, H, N.

### 2-(4-(Naphthalen-1-yl)piperazin-1-yl)-*N*-(*m*-tolyl)acetamide (**13**; CAB02-011HP) {#sec5.3.8}

Compound **13** was synthesized as described for **6** using K~2~CO~3~ (2.62 g, 18.9 mmol), NaI (50.0 mg), 1-(naphthalen-1-yl)piperazine^[@ref29]^ (670 mg, 3.16 mmol), and 2-chloro-*N*-(*m*-tolyl)acetamide (580 mg, 3.16 mmol) in an anhydrous acetonitrile (6 mL) solution. The crude product was purified by column chromatography (40--60% EtOAc/hexanes gradient) to give pure product **13** (546 mg, 48% yield) as a brown oil; ^1^H NMR (400 MHz, CDCl~3~): δ 9.17 (s, 1H), 8.20 (d, *J* = 7.5 Hz, 1H), 7.85 (s, 1H), 7.60 (d, *J* = 8.2 Hz, 1H), 7.55--7.47 (m, 2H), 7.43 (d, *J* = 11.4 Hz, 3H), 7.24 (d, *J* = 8.4 Hz, 1H), 7.15 (d, *J* = 7.3 Hz, 1H), 6.96 (d, *J* = 7.4 Hz, 1H), 3.34--3.27 (m, 2H), 3.23 (br s, 4H), 2.95 (br s, 4H), 2.38 (s, 3H). Anal. (C~23~H~25~N~3~O·2HCl) C, H, N.

### 3-Chloro-*N*-(*m*-tolyl)propanamide (**14**) {#sec5.3.9}

Compound **14** was synthesized as described for **5** by adding 3-chloropropanoyl chloride (1.30 g, 10.3 mmol) to a solution of *m*-toluidine (1 mL, 9.33 mmol) in ethyl acetate (30 mL) and triethylamine (1.44 mL). The crude product was purified by column chromatography (20--80% EtOAc/hexanes gradient) to give compound **14** (1.43 g, 78% yield) as a white solid. ^1^H NMR (CDCl~3~): δ 7.44 (s, 1H), 7.36--7.22 (m, 2H), 6.99 (d, *J* = 7.4 Hz, 1H), 3.96--3.92 (m, 2H), 2.85 (t, *J* = 6.3 Hz, 2H), 2.39 (s, 3H).

### 3-(4-(Pyridin-2-yl)piperidin-1-yl)-*N*-(*m*-tolyl)propanamide (**15**; CAB02-120) {#sec5.3.10}

Compound **15** was synthesized as described for **6** using K~2~CO~3~ (1.26 g, 7.56 mmol), NaI (50.0 mg), 2-(piperidin-4-yl)pyridine (246 mg, 1.52 mmol), and 3-chloro-*N*-(*m*-tolyl)propanamide (300 mg, 1.52 mmol) in an anhydrous acetonitrile (6 mL) solution. The crude product was purified by column chromatography (50--50% EtOAc/hexanes gradient) to give pure product **15** (325 mg, 66% yield) as a light brown oil; ^1^H NMR (400 MHz, CDCl~3~): δ 11.08 (s, 1H), 8.55 (d, *J* = 4.6 Hz, 1H), 7.69--7.61 (m, 1H), 7.45 (s, 1H), 7.29 (d, *J* = 7.5 Hz, 1H), 7.23--7.12 (m, 3H), 6.88 (d, *J* = 7.5 Hz, 1H), 3.21 (d, *J* = 11.2 Hz, 2H), 2.87--2.70 (m, 3H), 2.53 (t, *J* = 5.7 Hz, 2H), 2.34 (s, 3H), 2.24 (t, *J* = 11.6 Hz, 2H), 2.09 (d, *J* = 13.2 Hz, 2H), 2.02--1.87 (m, 2H). Anal. (C~20~H~25~N~3~O·2HCl·3.5H~2~O) C, H, N.

### 3-(4-(Pyridin-2-yl)piperazin-1-yl)-*N*-(*m*-tolyl)propanamide (**16**; CAB02-142) {#sec5.3.11}

Compound **16** was synthesized as described for **6** using K~2~CO~3~ (1.26 g, 9.12 mmol), 1-(pyridin-2-yl)piperazine (248 mg, 1.52 mmol), and 3-chloro-*N*-(*m*-tolyl)propanamide (300 mg, 1.52 mmol) in an anhydrous acetonitrile (6 mL) solution. The crude product was purified by column chromatography (50--50% EtOAc/hexanes gradient) to give pure product **16** (350 mg, 71% yield) as a white solid. mp 99--101 °C; ^1^H NMR (400 MHz CDCl~3~): δ 10.74 (s, 1H), 8.21 (br s, 1H), 7.51 (d, *J* = 8.0 Hz, 1H), 7.40 (s, 1H), 7.24 (d, *J* = 5.7 Hz, 1H), 7.15 (td, *J* = 8.2, 3.3 Hz, 1H), 6.86 (d, *J* = 7.3 Hz, 1H), 6.68 (q, *J* = 7.4, 5.6 Hz, 2H), 3.64 (d, *J* = 6.4 Hz, 4H), 2.81--2.65 (m, 6H), 2.55 (q, *J* = 4.7 Hz, 2H), 2.30 (s, 3H). Anal. (C~19~H~24~N~4~O·3HCl) C, H, N.

### 3-(4-(Pyrimidin-2-yl)piperazin-1-yl)-*N*-(*m*-tolyl)propanamide (**17**; RNB01-007) {#sec5.3.12}

Compound **17** was synthesized as described for **6** using K~2~CO~3~ (1.26 g, 9.12 mmol), 2-(piperazin-1-yl)pyrimidine (249 mg, 1.52 mmol), and 3-chloro-*N*-(*m*-tolyl)propanamide (350 mg, 1.52 mmol) in an anhydrous acetonitrile (6 mL) solution. The crude product was purified by column chromatography (50--50% EtOAc/hexanes gradient) to give pure product **17** (321 mg, 56% yield) as a cream solid. mp 85--86 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 10.76 (s, 1H), 8.33 (dt, *J* = 5.1, 2.4 Hz, 2H), 7.40 (s, 1H), 7.32--7.23 (m, 1H), 7.21--7.13 (m, 1H), 6.88 (d, *J* = 7.5 Hz, 1H), 6.54 (dp, *J* = 5.0, 2.6, 2.1 Hz, 1H), 3.94 (t, *J* = 4.8 Hz, 4H), 2.77 (t, *J* = 5.7 Hz, 2H), 2.67 (t, *J* = 4.6 Hz, 4H), 2.57 (q, *J* = 5.7, 5.0 Hz, 2H), 2.32 (s, 3H). Anal. (C~18~H~23~N~5~O·HCl) C, H, N.

### 2-Chloro-*N*-(3-ethylphenyl)acetamide (**19**) {#sec5.3.13}

Compound **19** was synthesized as described for **5** by adding 2-chloroacetyl chloride (3.62 mL, 45.4 mmol) to a solution of 3-ethylaniline (5.13 mL, 41.3 mmol) in ethyl acetate (30 mL) and triethylamine (1.44 mL). The crude product was purified by column chromatography (20--80% EtOAc/hexanes gradient) to give compound **19** (8.00 g, 98% yield) as a cream solid. ^1^H NMR (400 MHz, CDCl~3~): δ 8.23 (s, 1H), 7.47--7.38 (m, 2H), 7.32--7.27 (m, 1H), 7.04 (d, *J* = 7.5 Hz, 1H), 4.20 (s, 2H), 2.75--2.58 (m, 2H), 1.28--1.22 (m, 3H).

### *N*-(3-Ethylphenyl)-2-(4-(pyridin-2-yl)piperidin-1-yl)acetamide (**20**; CAB02-021HP) {#sec5.3.14}

Compound **20** was synthesized as described for **6** using K~2~CO~3~ (1.54 g, 11.17 mmol), 2-(piperidin-4-yl)pyridine (300 mg, 1.86 mmol), and 2-chloro-*N*-(3-ethylphenyl)acetamide (368 mg, 1.86 mmol) in an anhydrous acetonitrile (6 mL) solution. The crude product was purified by column chromatography (40--60% EtOAc/hexanes gradient) to give pure product **20** (435 mg, 73% yield) as a white solid. mp 56--58 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 9.16 (s, 1H), 7.48--7.38 (m, 2H), 7.33 (d, *J* = 7.4 Hz, 2H), 7.26 (br s, 4H), 6.97 (d, *J* = 7.5 Hz, 1H), 3.16 (d, *J* = 3.3 Hz, 2H), 3.05 (d, *J* = 11.5 Hz, 2H), 2.66 (d, *J* = 7.9 Hz, 2H), 2.60--2.54 (m, 1H), 2.40 (t, *J* = 12.0 Hz, 2H), 1.87 (dt, *J* = 38.0, 13.2 Hz, 4H), 1.25 (t, *J* = 7.3, 5.9 Hz, 3H). Anal. (C~20~H~25~N~3~O·C~2~H~2~O~4~) C, H, N.

### *N*-(3-Ethylphenyl)-2-(4-(pyridin-2-yl)piperazin-1-yl)acetamide (**21**; CAB02-017HP) {#sec5.3.15}

Compound **21** was synthesized as described for **6** using K~2~CO~3~ (2.74 g, 19.8 mmol), 1-(pyridin-2-yl)piperazine (539 mg, 3.30 mmol), and 2-chloro-*N*-(3-ethylphenyl)acetamide (650 mg, 3.30 mmol) in an anhydrous acetonitrile (8 mL) solution. The crude product was purified by column chromatography (50--50% EtOAc/hexanes gradient) to give pure product **21** (792 mg, 74% yield) as a white solid. mp 109--111 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 9.07 (s, 1H), 8.19 (s, 1H), 7.54--7.44 (m, 1H), 7.38 (d, *J* = 8.0 Hz, 2H), 7.27--7.20 (m, 1H), 6.95 (d, *J* = 7.6 Hz, 1H), 6.66 (d, *J* = 8.6 Hz, 2H), 3.60 (d, *J* = 6.0 Hz, 4H), 3.17 (t, *J* = 2.3 Hz, 2H), 2.73 (d, *J* = 5.0 Hz, 4H), 2.61 (t, *J* = 8.0 Hz, 2H), 1.26--1.15 (m, 3H). Anal. (C~19~H~24~N~4~O·2HCl·3/4H~2~O) C, H, N.

### 2-(4-(5-Chloropyridin-2-yl)piperazin-1-yl)-*N*-(3-ethylphenyl)acetamide (**22**; CAB02-019HP) {#sec5.3.16}

Compound **22** was synthesized as described for **6** using K~2~CO~3~ (1.26 g, 9.12 mmol), 1-(5-chloropyridin-2-yl)piperazine (300 mg, 1.52 mmol), and 2-chloro-*N*-(3-ethylphenyl)acetamide (300 mg, 1.52 mmol) in an anhydrous acetonitrile (6 mL) solution. The crude product was purified by column chromatography (20--80% EtOAc/hexanes gradient) to give pure product **22** (480 mg, 88% yield) as a white solid. mp 101--103 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 9.03 (s, 1H), 8.11 (s, 1H), 7.46--7.34 (m, 3H), 7.25--7.23 (m, 1H), 6.95 (d, *J* = 7.5 Hz, 1H), 6.59 (d, *J* = 8.9 Hz, 1H), 3.57 (t, *J* = 4.9 Hz, 4H), 3.17 (d, *J* = 2.7 Hz, 2H), 2.71 (t, *J* = 4.7 Hz, 4H), 2.61 (t, *J* = 8.1 Hz, 2H), 1.32--1.13 (m, 3H). Anal. (C~19~H~23~ClN~4~O·2HCl·3/4H~2~O) C, H, N.

### 2-Chloro-*N*-(pyridin-3-yl)acetamide (**24a**) {#sec5.3.17}

Compound **24a** was synthesized as described for **5** by adding 2-chloroacetyl chloride (0.71 mL, 17.5 mmol) to a solution of pyridin-3-amine (1.50 g, 16.0 mmol) in ethyl acetate (25 mL) and triethylamine (0.4 mL). The crude product was purified by column chromatography (20--80% EtOAc/hexanes gradient) to give **24a** (1.17 g, 43% yield) as a white solid. ^1^H NMR (400 MHz, D~2~O): δ 9.37--9.08 (m, 1H), 8.60--8.32 (m, 2H), 8.06--7.87 (m, 1H), 5.67 (s, 2H).

### 2-Chloro-*N*-(pyrimidin-5-yl)acetamide (**24b**) {#sec5.3.18}

Compound **24b** was synthesized as described for **5** by adding 2-chloroacetyl chloride (0.46 mL, 5.78 mmol) to a solution of pyrimidin-5-amine (500 mg, 5.26 mmol) in ethyl acetate (10 mL) and triethylamine (0.4 mL). The crude product was purified by column chromatography (20--80% EtOAc/hexanes gradient) to give **24b** (510 mg, 57% yield) as a brown solid. ^1^H NMR (400 MHz, D~2~O): δ 9.17 (s, 1H), 8.54 (s, 2H), 8.01 (s, 1H), 5.66 (s, 2H).

### 2-(4-(Pyridin-2-yl)piperazin-1-yl)-*N*-(pyridin-3-yl)acetamide (**25**; CAB02-033HP) {#sec5.3.19}

Compound **25** was synthesized as described for **6** using K~2~CO~3~ (1.27 g, 9.17 mmol), 1-(pyridin-2-yl)piperazine (249 mg, 1.52 mmol), and compound **24a** 2-chloro-*N*-(pyridin-3-yl)acetamide (260 mg, 1.52 mmol) in an anhydrous acetonitrile (6 mL) solution. The crude product was purified by column chromatography (20--80% EtOAc/hexanes gradient) to give pure product **25** (287 mg, 63% yield) as a white solid. mp 173--174 °C; ^1^H NMR (400 MHz CDCl~3~): δ 9.23 (s, 1H), 8.59 (s, 1H), 8.37 (s, 1H), 8.23 (d, *J* = 12.8 Hz, 2H), 7.51 (s, 1H), 6.68 (d, *J* = 8.1 Hz, 2H), 3.63 (br s, 4H), 3.23 (d, *J* = 2.9 Hz, 2H), 2.76 (br s, 4H). Anal. (C~16~H~19~N~5~O·4HCl·1.1H~2~O·1/4C~3~H~8~O) C, H, N.

### 2-(4-(5-Chloropyridin-2-yl)piperazin-1-yl)-*N*-(pyridin-3-yl)acetamide (**26**; CAB02-035HP) {#sec5.3.20}

Compound **26** was synthesized as described for **6** using K~2~CO~3~ (2.63 g, 19.0 mmol), 1-(5-chloropyridin-2-yl)piperazine (627 mg, 3.17 mmol), and compound **24a** 2-chloro-*N*-(pyridin-3-yl)acetamide (540 mg, 3.17 mmol) in an anhydrous acetonitrile (6 mL) solution. The crude product was purified by column chromatography (20--80% EtOAc/hexanes gradient) to give pure product **26** (721 mg, 68% yield) as a white solid. mp 155--156 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 9.17 (s, 1H), 8.57 (s, 1H), 8.36 (br s, 1H), 8.22 (d, *J* = 8.2 Hz, 1H), 8.12 (s, 1H), 7.49--7.39 (m, 1H), 7.31--7.27 (m, 1H), 6.60 (d, *J* = 9.1 Hz, 1H), 3.59 (s, 4H), 3.25--3.15 (m, 2H), 2.74 (d, *J* = 5.0 Hz, 4H). Anal. (C~16~H~18~ClN~5~O·4HCl·H~2~O·1/2C~3~H~8~O) C, H, N.

### 2-(4-(Pyridin-2-yl)piperazin-1-yl)-*N*-(pyrimidin-5-yl)acetamide (**27**; CAB02-029HP) {#sec5.3.21}

Compound **27** was synthesized as described for **6** using K~2~CO~3~ (1.45 g, 10.5 mmol), 1-(pyridin-2-yl)piperazine (285 mg, 1.75 mmol), and compound **24b** 2-chloro-*N*-(pyrimidin-5-yl)acetamide (300 mg, 1.75 mmol) in an anhydrous acetonitrile (6 mL) solution. The crude product was purified by column chromatography (20--80% EtOAc/hexanes gradient) to give pure product **27** (268 mg, 51% yield) as a white solid. mp 144--146 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 9.17 (s, 1H), 9.02--8.81 (m, 3H), 8.13 (br s, 1H), 7.43 (br s, 1H), 6.60 (br s, 2H), 3.56 (br s, 4H), 3.18 (br s, 2H), 2.69 (br s, 4H). Anal. (C~15~H~18~N~6~O·3/2C~2~H~2~O~4~·3/4H~2~O) C, H, N.

### 2-(4-(5-Chloropyridin-2-yl)piperazin-1-yl)-*N*-(pyrimidin-5-yl)acetamide (**28**; CAB02-031HP) {#sec5.3.22}

Compound **28** was synthesized as described for **6** using K~2~CO~3~ (866 mg, 6.26 mmol), 1-(5-chloropyridin-2-yl)piperazine (207 mg, 1.04 mmol), and compound **24b** 2-chloro-*N*-(pyrimidin-5-yl)acetamide (180 mg, 1.04 mmol) in an anhydrous acetonitrile (6 mL) solution. The crude product was purified by column chromatography (20--80% EtOAc/hexanes gradient) to give pure product **28** (157 mg, 45% yield) as a yellowish oil; ^1^H NMR (400 MHz, CDCl~3~): δ 9.21 (s, 1H), 9.08--8.98 (m, 3H), 8.15 (d, *J* = 3.7 Hz, 1H), 7.47 (d, *J* = 8.9 Hz, 1H), 6.63 (d, *J* = 9.2 Hz, 1H), 3.62 (br s, 4H), 3.30--3.23 (m, 2H), 2.77 (br s, 4H). Anal. (C~15~H~17~ClN~6~O·C~2~H~2~O~4~·1.5H~2~O) C, H, N.

Radioligand Binding Studies {#sec5.4}
---------------------------

HEK293 cells stably expressing human D~2L~R, D~3~R, or D~4.4~R were grown in a 50:50 mix of Ham's F12 and Dulbecco's modified Eagle's medium culture media, supplemented with 2 mM [l]{.smallcaps}-glutamine, 20 mM *N*-(2-hydroxyethyl)piperazine-*N*′-ethanesulfonic acid (HEPES), 0.1 mM non-essential amino acids, 1× antibiotic/antimycotic, 10% heat-inactivated fetal bovine serum, and 200 μg/mL hygromycin (Life Technologies, Grand Island, NY) and grown in an incubator at 37 °C and 5% CO~2~. Upon reaching 80--90% confluence, cells were harvested using pre-mixed Earle's balanced salt solution (EBSS) with 5 mM ethylenediaminetetraacetic acid (EDTA) (Life Technologies) and centrifuged at 3000 rpm for 10 min at 21 °C. The supernatant was removed and the cell pellet was resuspended in 10 mL hypotonic lysis buffer (5 mM Tris, 5 mM MgCl~2~, pH 7.4 at 4 °C) and then centrifuged at 20000 rpm for 30 min at 4 °C. The membrane pellet was resuspended in fresh binding buffer for either \[^3^H\]*N*-methylspiperone (PerkinElmer, Waltham, MA) binding experiments \[fresh EBSS buffer made from 8.7 g/L Earle's balanced salts without phenol red (US Biological, Salem, MA), 2.2 g/L sodium bicarbonate, pH 7.4\] or \[^3^H\]-(*R*)-(+)-7-OH-DPAT (ARC, Saint Louis, MO) binding experiments (50 mM Tris, 10 mM MgCl~2~, 1 mM EDTA, pH 7.4). A Bradford protein assay (Bio-Rad, Hercules, CA) was used to determine the protein concentration. Membranes were used fresh for \[^3^H\]-(*R*)-(+)-7-OH-DPAT binding experiments or diluted to 500 μg/mL and stored in a −80 °C freezer for later use in \[^3^H\]*N*-methylspiperone binding experiments.

All test compounds were freshly dissolved in 30% dimethyl sulfoxide (DMSO) and 70% H~2~O to a stock concentration of 100 μM. To assist the solubilization of free-base compounds, 10 μL of glacial acetic acid was added along with the DMSO. Each test compound was then diluted into half-log serial dilutions and tested in triplicate using the 30% DMSO vehicle. Competitive-inhibition experiments were conducted in 96-well plates containing 300 μL fresh binding buffer, 50 μL of diluted test compound, 100 μL of membrane suspension (\[^3^H\]*N*-methylspiperone: 20 μg/well for D~2~R and D~3~R, 30 μg/well for D~4~R; \[^3^H\]-(*R*)-(+)-7-OH-DPAT: 80 μg/well for D~2~R, 40 μg/well for D~3~R, 60 μg/well for D~4~R), and 50 μL of radioligand diluted in binding buffer (\[^3^H\]*N*-methylspiperone: 0.4 nM final concentration for all receptors; \[^3^H\]-(*R*)-(+)-7-OH-DPAT: 1.5 nM final concentration for D~2~R, 0.5 nM final concentration for D~3~R, 3 nM final concentration for D~4~R). Aliquots of \[^3^H\]*N*-methylspiperone and \[^3^H\]-(*R*)-(+)-7-OH-DPAT solution were also quantified accurately to determine how much radioactivity was added. Nonspecific binding was determined using 10 μM (+)-butaclamol (Sigma-Aldrich, St. Louis, MO), and total binding was determined with 30% DMSO vehicle. The reaction was incubated for 60 (\[^3^H\]*N*-methylspiperone) or 90 min (\[^3^H\]-(*R*)-(+)-7-OH-DPAT) at room temperature and terminated by filtration through PerkinElmer UniFilter-96 GF/B plates, presoaked in 0.5% polyethylenimine, using a Brandel 96-well plate harvester manifold (Brandel Instruments, Gaithersburg, MD). Filters were washed three times (∼1 mL/well) with ice cold binding buffer. After drying, 65 μL PerkinElmer MicroScint 20 scintillation cocktail was added to each well and filters were counted after at least 18 h of incubation using a PerkinElmer MicroBeta Microplate Counter. IC~50~ values for each compound were determined from dose--response curves and *K*~i~ values were calculated using the Cheng--Prusoff equation in GraphPad Prism 6 (GraphPad Software, San Diego, CA).^[@ref50]^*K*~d~ values for \[^3^H\]*N*-methylspiperone and \[^3^H\]-(*R*)-(+)-7-OH-DPAT were determined via separate homologous competitive binding experiments at each receptor. *K*~i~ values for each compound/receptor/radioligand combination were calculated from at least three independent experiments and are reported as means ± SEM.

Functional Assays {#sec5.5}
-----------------

### β-Arrestin Recruitment Assay {#sec5.5.1}

Assays were conducted with minor modifications as previously published by our laboratory,^[@ref31],[@ref51]−[@ref54]^ using the DiscoverX PathHunter technology (DiscoverX, Inc., Fremont, CA). Briefly, CHO-K1 cells stably expressing the human D~2~R long isoform, D~3~R, or D~4~R (DiscoverX, Inc.), were maintained in Ham's F12 media supplemented with 10% fetal bovine serum, 100 U/mL penicillin, 100 μg/mL streptomycin, and 800 μg/mL G418 and 300 μg/mL hygromycin at 37 °C, 5% CO~2~, and 90% humidity. The cells were seeded in this media at a density of 2625 cells/well in 384-well black, clear-bottom plates. Compounds were diluted in phosphate-buffered saline in the presence of 0.2 μM sodium metabisulfite. Following overnight incubation, the cells were treated with multiple concentrations of compound and incubated at 37 °C for 90 min. DiscoverX reagent was then added to cells according to the manufacturer's recommendations followed by 45--60 min incubation at room temperature. Luminescence was measured on a Hamamatsu FDSS μCell reader. Data were collected as RLUs and subsequently normalized to a percentage of the control luminescence seen with a maximum concentration of dopamine for agonist mode assays and the EC~80~ of dopamine for antagonist mode assays. The Hill coefficients of the concentration--response curves did not significantly differ from unity.

### cAMP Inhibition Assay {#sec5.5.2}

D~4~R- and D~2~R-mediated inhibition of forskolin-stimulated cAMP production was assayed using the PerkinElmer LANCE Ultra cAMP assay kit (PerkinElmer, Inc., Waltham, MA). CHO-K1 cells stably expressing the human D~2~R long isoform or D~4~R were maintained in Ham's F12 supplemented with 10% fetal bovine serum, 100 U/mL penicillin, 100 μg/mL streptomycin, and 800 μg/mL G418 and 300 μg/mL hygromycin at 37 °C, 5% CO~2~, and 90% humidity. Cells were seeded in Hank's balanced salt solution (with CaCl and MgCl~2~) with 5 mM HEPES buffer and 0.2 μM sodium metabisulfite at a density of 5000 cells/well in 384-well white plates. Compounds and forskolin were made in the same buffer. Immediately after plating, cells were treated with 2.5 μL of compound (at various concentrations) and 2.5 μL of forskolin and incubated at room temperature for 30 min. The final concentration of forskolin was 10 μM. When running assay in antagonist mode, the EC~80~ of dopamine (10 nM) was added with the forskolin solution. Eu-cAMP tracer and ULight-anti-cAMP solutions were added as directed by the manufacturer and cells were incubated for 2 h in the dark at room temperature, after which a time-resolved fluorescence resonance energy transfer (TR-FRET) signal was measured using a BMG Labtech PHERAstar Fs (BMG Labtech USA, Cary, NC). Values were normalized to a percentage of the control TR-FRET signal seen with a maximum concentration of dopamine for agonist mode assays and the EC~80~ of dopamine for antagonist mode assays. The Hill coefficients of the concentration--response curves did not significantly differ from unity with the data fitting to a single site model.

Molecular Docking Studies {#sec5.6}
-------------------------

### Crystal Structures of D~2~R, D~3~R, and D~4~R {#sec5.6.1}

In this study, we used the crystal structure of the human dopamine D~2~, D~3~, and D~4~ receptor in complex with antagonists risperidone (PDB: 6CM4([@ref26])), eticlopride (PDB: 3PBL([@ref25])), and nemonapride (PDB: 5WIU([@ref24])), respectively. Each of the three crystal structures was prealigned in membrane using the OPM web server.^[@ref55]^

### Protein Structure Preparation {#sec5.6.2}

The structures of D~2~R, D~3~R, and D~4~R were further prepared using Maestro Protein Preparation Wizard.^[@ref56]^ First, the hydrogens and missing side chains were added. Second, the protonation state of the receptor was optimized at pH = 7. Third, a restrained minimization was performed to relax the receptor structure using OPLS3 force field.^[@ref57]^

### Ligand Preparation {#sec5.6.3}

The 2D structures of **1**, **6**, **9**, **10**, **12**, **13**, and **21** were first constructed in ChemDraw and then converted into a 3D structure using Maestro Elements. Next, the protonation state was generated at pH = 7 using the p*K*~a~ prediction program Epik that is based on the Hammett and Taft methodologies.^[@ref56]^ Lastly, the geometry of each ligand was optimized using an energy minimization.

### Ligand Docking {#sec5.6.4}

The orthosteric ligand pockets of D~2~R, D~3~R, and D~4~R were specified by the crystal ligands risperidone, eticlopride, and nemonapride, respectively, and a 3D box was formed around each crystal ligand to enclose the orthosteric ligand binding pocket. Each ligand was first docked using the Glide XP scoring function with default procedures and parameters.^[@ref58],[@ref59]^ Reproductions of the crystal binding poses of risperidone, eticlopride, and nemonapride in D~2~R, D~3~R, and D~4~R, respectively, provide a solid validation for our XP docking protocol ([Figures S2--S4](http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.9b00231/suppl_file/jm9b00231_si_001.pdf)). To refine the docking poses of noncrystal ligands, induced fit docking (IFD) was conducted on the complex from the Glide XP docking.

### MD Simulation System Setup {#sec5.6.5}

Seven MD simulation systems were built using the complexes from the IFD. Each pre-aligned complex was placed in a double lipid membrane formed by 1-palmitoyl-2-oleoyl-*sn*-glycero-3-phosphocholine lipids^[@ref60]^ and then solvated in an orthorhombic water box with a buffer distance of 10 Å using the SPC water model.^[@ref61]^ Each system was neutralized using Na^+^ ions, added with a salt concentration of 0.15 M NaCl. The OPLS3 force field^[@ref57]^ was used to represent the receptor--ligand--lipid system.

### Relaxation and Production Runs {#sec5.6.6}

Using Desmond, each system was first relaxed using the default relaxation protocol for membrane proteins.^[@ref62]^ After the relaxation, a 100.0 ns production run was conducted under the *NPT* ensemble for each system using the default protocol. A temperature of 300 K was controlled using the Nosé--Hoover chain coupling scheme^[@ref63]^ with a coupling constant of 1.0 ps. A pressure of 1 atm was controlled using the Martyna--Tuckerman--Klein chain coupling scheme^[@ref63]^ with a coupling constant of 2.0 ps. M-SHAKE^[@ref64]^ was applied to constrain all bonds connecting hydrogen atoms, enabling a 2.0 fs time step in the simulations. The *k*-space Gaussian split Ewald method^[@ref65]^ was used to treat long-range electrostatic interactions under periodic boundary conditions (charge grid spacing of ∼1.0 Å, and direct sum tolerance of 10^--9^). The cutoff distance for short-range nonbonded interactions was 9 Å, with the long-range van der Waals interactions based on a uniform density approximation. To reduce the computation, nonbonded forces were calculated using an r-RESPA integrator^[@ref66]^ where the short-range forces were updated every step and the long-range forces were updated every three steps. The trajectories were saved at 100.0 ps intervals for analysis.

### SID Analyses {#sec5.6.7}

The SID tool was used to generate graphical information about the behavior and interaction of the protein and ligand during simulation. The analysis gives us graphical representation of root mean square deviation (RMSD), root mean square fluctuation, secondary structures changes, protein--ligand contacts, and ligand torsion profiles of rotatable bonds.

### Convergence of Simulations {#sec5.6.8}

To check the convergence of the simulations, we investigated the protein Cα and ligand RMSD plots for each system ([Figures S34--S36](http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.9b00231/suppl_file/jm9b00231_si_001.pdf)). The relatively flat plots within last 20 ns indicate that the complex systems have reached a steady state.

### Trajectory Clustering Analyses {#sec5.6.9}

The Desmond trajectory clustering tool^[@ref67]^ was used to group complex structures for each system. The backbone RMSD matrix was used as structural similarity metric and hierarchical clustering with average linkage^[@ref67]^ was selected as the clustering method. The merging distance cutoff was set to be 2.5 Å. For all systems, a dominant cluster with was identified to have more than 80% of the trajectory population.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acs.jmedchem.9b00231](http://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.9b00231).Representation of compound effects on D~1~-like dopamine receptors and comparison of ligand--residue contacts in the D~2~-like receptors; list of MD simulations and the examples of validation analysis; and elemental analysis for all final compounds results and liquid chromatography/mass spectrometry data for compound **9** ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.9b00231/suppl_file/jm9b00231_si_001.pdf))SMILES data ([CSV](http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.9b00231/suppl_file/jm9b00231_si_002.csv))
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TM

:   transmembrane

D~2~R

:   dopamine D~2~ receptor

D~3~R

:   dopamine D~3~ receptor

D~4~R

:   dopamine D~4~ receptor

CDCl~3~

:   deuterated chloroform

D~2~O

:   deuterium oxide

EtOAc

:   ethyl acetate

PP

:   phenylpiperazine
